We indeed used a suboptimal dose of oxaliplatin (3 mg/kg) on purpose, as we knew that such a concentration did not have a significant effect on tumor growth in our model but was still inducing the overexpression of membrane CLDN1 as shown in Fig. 2F. This protocol was repeated for 4 weeks. The gene discussed is CLDN1; the disease is neoplasm.